Institution
Jagiellonian University
Education•Krakow, Poland•
About: Jagiellonian University is a education organization based out in Krakow, Poland. It is known for research contribution in the topics: Population & Catalysis. The organization has 17438 authors who have published 44092 publications receiving 862633 citations. The organization is also known as: Academia Cracoviensis & Akademia Krakowska.
Papers published on a yearly basis
Papers
More filters
••
1,511 citations
••
TL;DR: This review summarizes knowledge about Nrf2 and HO-1 across different phyla suggesting their conservative role as stress-protective and anti-aging factors.
Abstract: The multifunctional regulator nuclear factor erythroid 2-related factor (Nrf2) is considered not only as a cytoprotective factor regulating the expression of genes coding for anti-oxidant, anti-inflammatory and detoxifying proteins, but it is also a powerful modulator of species longevity. The vertebrate Nrf2 belongs to Cap ‘n’ Collar (Cnc) bZIP family of transcription factors and shares a high homology with SKN-1 from Caenorhabditis elegans or CncC found in Drosophila melanogaster. The major characteristics of Nrf2 are to some extent mimicked by Nrf2-dependent genes and their proteins including heme oxygenase-1 (HO-1), which besides removing toxic heme, produces biliverdin, iron ions and carbon monoxide. HO-1 and their products exert beneficial effects through the protection against oxidative injury, regulation of apoptosis, modulation of inflammation as well as contribution to angiogenesis. On the other hand, the disturbances in the proper HO-1 level are associated with the pathogenesis of some age-dependent disorders, including neurodegeneration, cancer or macular degeneration. This review summarizes our knowledge about Nrf2 and HO-1 across different phyla suggesting their conservative role as stress-protective and anti-aging factors.
1,490 citations
••
University of Texas MD Anderson Cancer Center1, Cornell University2, Rutgers University3, Barts Health NHS Trust4, University of Wisconsin-Madison5, Jagiellonian University6, Stanford University7, University of Virginia8, Hofstra University9, University of Manchester10, University of Ulm11, Ludwig Maximilian University of Munich12, Medical University of Warsaw13, University of Southampton14, Oregon Health & Science University15, Ohio State University16
TL;DR: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Abstract: rolled into two groups: those who had previously received at least 2 cycles of bor - tezomib therapy and those who had received less than 2 complete cycles of bortezo - mib or had received no prior bortezomib therapy. The primary end point was the overall response rate. Secondary end points were duration of response, progression- free survival, overall survival, and safety. RESULTS The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic factors. Patients had received a median of three prior therapies. The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytope - nia (in 11%), and anemia (in 10%). A response rate of 68% (75 patients) was observed, with a complete response rate of 21% and a partial response rate of 47%; prior treat - ment with bortezomib had no effect on the response rate. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months (95% confidence interval (CI), 15.8 to not reached), the estimated median progression- free survival was 13.9 months (95% CI, 7.0 to not reached), and the median overall survival was not reached. The estimated rate of overall survival was 58% at 18 months. CONCLUSIONS Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)
1,389 citations
••
TL;DR: In this article, the authors propose a voltage-sensitive voltage-controlled voltage gate to the point contact region of a ballistic point contact with zigzag edges, where the polarity can be inverted by local application of a gate voltage to the region.
Abstract: The potential of graphene for carbon electronics rests on the possibilities offered by its unusual band structure to create devices that have no analogue in silicon-based electronics1,2. Conduction and valence bands in graphene form conically shaped valleys, touching at a point called the Dirac point. There are two inequivalent Dirac points in the Brillouin zone, related by time-reversal symmetry. Intervalley scattering is suppressed in pure samples3,4,5. The independence and degeneracy of the valley degree of freedom suggests that it might be used to control an electronic device6, in much the same way as the electron spin is used in spintronics7 or quantum computing8. A key ingredient for ‘valleytronics’ would be a controllable way of occupying a single valley in graphene, thereby producing a valley polarization. Here we propose such a valley filter, based on a ballistic point contact with zigzag edges. The polarity can be inverted by local application of a gate voltage to the point contact region. Two valley filters in series may function as an electrostatically controlled valley valve, representing a zero-magnetic-field counterpart to the familiar spin valve.
1,380 citations
••
TL;DR: A review of the literature on enzymes immobilized on chitin- and chitosan-based materials, covering the last decade, is presented in this paper, where one hundred fifty-eight papers on 63 immobilized enzymes for multiplicity of applications ranging from wine, sugar and fish industry, through organic compounds removal from wastewaters to sophisticated biosensors for both in situ measurements of environmental pollutants and metabolite control in artificial organs, are reviewed.
1,317 citations
Authors
Showing all 17729 results
Name | H-index | Papers | Citations |
---|---|---|---|
Roxana Mehran | 141 | 1378 | 99398 |
Brad Abbott | 137 | 1566 | 98604 |
M. Morii | 134 | 1664 | 102074 |
M. Franklin | 134 | 1581 | 95304 |
John Huth | 131 | 1087 | 85341 |
Wladyslaw Dabrowski | 129 | 990 | 79728 |
Rostislav Konoplich | 128 | 811 | 73790 |
Michel Vetterli | 128 | 901 | 76064 |
Francois Corriveau | 128 | 1022 | 75729 |
Christoph Falk Anders | 126 | 734 | 68828 |
Tomasz Bulik | 121 | 698 | 86211 |
Elzbieta Richter-Was | 118 | 793 | 69127 |
S. H. Robertson | 116 | 1311 | 58582 |
S. J. Chen | 116 | 1559 | 62804 |
David M. Stern | 107 | 271 | 47461 |